NASDAQ:XENEXenon Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.03 -0.12 (-0.99 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$11.70Now: $12.03▼$12.4550-Day Range$11.57MA: $12.86▼$14.9052-Week Range$7.00Now: $12.03▼$18.45Volume74,060 shsAverage Volume259,324 shsMarket Capitalization$420.74 millionP/E RatioN/ADividend YieldN/ABeta1.31 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.67, Xenon Pharmaceuticals has a potential upside of 96.7% from its current price of $12.03.Amount of Analyst CoverageXenon Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesXenon Pharmaceuticals has received 354 “outperform” votes. (Add your “outperform” vote.)Underperform VotesXenon Pharmaceuticals has received 296 “underperform” votes. (Add your “underperform” vote.)Community SentimentXenon Pharmaceuticals has received 54.46% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote “Outperform” if you believe XENE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $113,240.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions79.24% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($0.85) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 4.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XENE Previous Symbol CUSIPN/A CIK1582313 Webwww.xenon-pharma.com Phone604-484-3300Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.83 million Price / Sales61.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.99 per share Price / Book4.02Profitability EPS (Most Recent Fiscal Year)($1.54) Net Income$-41,600,000.00 Net MarginsN/A Return on Equity-37.15% Return on Assets-25.60%Miscellaneous Employees89 Outstanding Shares34,974,000Market Cap$420.74 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:XENE Rates by TradingView Receive XENE News and Ratings via Email Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions How has Xenon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XENE shares have decreased by 5.4% and is now trading at $12.03. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Xenon Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Xenon Pharmaceuticals. When is Xenon Pharmaceuticals' next earnings date? Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Xenon Pharmaceuticals. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc (NASDAQ:XENE) posted its quarterly earnings results on Thursday, May, 21st. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.10. The biopharmaceutical company had revenue of $7.08 million for the quarter, compared to analysts' expectations of $7.50 million. View Xenon Pharmaceuticals' earnings history. What price target have analysts set for XENE? 4 brokerages have issued 1-year price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $23.00 to $25.00. On average, they expect Xenon Pharmaceuticals' share price to reach $23.67 in the next year. This suggests a possible upside of 96.7% from the stock's current price. View analysts' price targets for Xenon Pharmaceuticals. Has Xenon Pharmaceuticals been receiving favorable news coverage? News coverage about XENE stock has been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news about Xenon Pharmaceuticals. Who are some of Xenon Pharmaceuticals' key competitors? Some companies that are related to Xenon Pharmaceuticals include Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Corcept Therapeutics (CORT), Ligand Pharmaceuticals (LGND), Xencor (XNCR), I-Mab (IMAB), Aurinia Pharmaceuticals (AUPH), Myovant Sciences (MYOV), Madrigal Pharmaceuticals (MDGL), Y-mAbs Therapeutics (YMAB), Akebia Therapeutics (AKBA), Ironwood Pharmaceuticals (IRWD), Epizyme (EPZM), BELLUS Health (BLUSF) and Intra-Cellular Therapies (ITCI). View all competitors. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Viking Therapeutics (VKTX), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Arbutus Biopharma (ABUS), Crispr Therapeutics (CRSP) and Dynavax Technologies (DVAX). Who are Xenon Pharmaceuticals' key executives? Xenon Pharmaceuticals' management team includes the following people: Simon Neil Pimstone, Chief Executive Officer & DirectorIan C. Mortimer, President, Chief Financial Officer & SecretaryErnesto Aycardi, Chief Medical OfficerRobin Sherrington, Executive VP-Business & Corporate DevelopmentCharles J. Cohen, Vice President-Biological Sciences What is Xenon Pharmaceuticals' stock symbol? Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE." How do I buy shares of Xenon Pharmaceuticals? Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Xenon Pharmaceuticals' stock price today? One share of XENE stock can currently be purchased for approximately $12.03. How big of a company is Xenon Pharmaceuticals? Xenon Pharmaceuticals has a market capitalization of $420.74 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-41,600,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe. What is Xenon Pharmaceuticals' official website? The official website for Xenon Pharmaceuticals is www.xenon-pharma.com. How can I contact Xenon Pharmaceuticals? Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
